| Bioactivity | Cav 3.2 inhibitor 3 (Compound 4) is a potent Cav3.2 T-type Ca2+ channel inhibitor with an IC50 of 0.1534 μM, and has little binding affinity to D2 receptors[1]. |
| In Vivo | Cav 3.2 inhibitor 3 (Compound 4) (1-10 mg/kg; i.p.; once) potently suppresses T-channel-dependent somatic and visceral pain in mice[1]. Animal Model: |
| Name | Cav 3.2 inhibitor 3 |
| Formula | C32H37N3O2 |
| Molar Mass | 495.66 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kasanami Y, et al. Discovery of pimozide derivatives as novel T-type calcium channel inhibitors with little binding affinity to dopamine D2 receptors for treatment of somatic and visceral pain. Eur J Med Chem. 2022 Aug 27;243:114716. |